CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
February 03 2010 - 8:00AM
PR Newswire (US)
VIENNA, Va., Feb. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(NYSE AMEX: CVM) announced that Geert Kersten, Chief Executive
Officer, will be presenting at the 2010 BIO CEO & Investor
Conference. Hosted by the Biotechnology Industry Organization
(BIO), the conference will take place February 8-9 at the
Waldorf=Astoria in New York. Mr. Kersten's presentation will be on
Tuesday, February 9th, at 1:30 p.m. EST. The presentation will be
webcast live with slides and archived until May 11, 2010. The
webcast can be accessed at
http://www.veracast.com/webcasts/bio/ceoinvestor2010/05209268.cfm.
About CEL-SCI Corporation CEL-SCI Corporation is developing
products that empower immune defenses. Its lead product Multikine®
is being readied for a global Phase III trial in advanced primary
head and neck cancer. CEL-SCI is also developing an immunotherapy
to treat H1N1 hospitalized patients using its L.E.A.P.S.(TM)
technology platform. This investigational treatment involves
non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and
the Spanish Flu as CEL-SCI scientists are very concerned about the
creation of a new more virulent hybrid virus through the
combination of H1N1 and Avian Flu, or maybe Spanish Flu. This
investigational treatment is currently being tested in a clinical
study at Johns Hopkins University. The Company has operations in
Vienna, Virginia, and in/near Baltimore, Maryland. For more
information, please visit http://www.cel-sci.com/. About The BIO
CEO & Investor Conference Now in its twelfth year, the BIO CEO
& Investor Conference 2010 is the largest investor conference
focused on the biotechnology industry. The conference provides a
forum for public and private equity investors, research analysts,
investment bankers and senior-level executives to learn about and
discuss investment trends and investment opportunities in the
biotechnology industry. This years' conference will feature
corporate presentations from more than 120 companies, workshops
featuring leading experts on specific therapeutic and technology
topics, plenary and panel sessions on timely business issues and
industry trends, many opportunities to schedule one-on-one
meetings, as well as numerous networking opportunities. For more
information, visit http://www.ceo.bio.org/. DATASOURCE: CEL-SCI
Corporation CONTACT: Gavin de Windt, CEL-SCI Corporation,
+1-703-506-9460 Web Site: http://www.cel-sci.com/
Copyright